HeyJaredBoutique Biotech
Boutique insights into the biotech stock market. Not investment advice.
- Indexed issues, last 90 days
- 19
- Latest publication
- Sep 30, 2026
- Audience
- Checking…
- Earliest in this view
- Aug 19, 2026
Latest issues
ALL/IN on Tenax Therapeutics? (opens the original)
Read excerpt
Not investment advice. Read the Liability/Disclaimer subsection for full context. Read more
ALL/IN on Viking Therapeutics? (opens the original)
Read excerpt
Earlier this week, we tweeted out that: First up in this new series is , hot on the heels of our most recent Viking spotlight post from last week, a name we’ve been following scrupulously since July - and for which we recently acquired the new proud moniker: “The Goofy Short”. Not investment advice. Read the <a href="https://boutiquebiotech.substack.com/about?utm_source=m
Latigo Biotherapeutics in the Spotlight (opens the original)
Read excerpt
Latigo Biotherapeutics ($LTGO) - in our opinion such a cool ticker name (like “let go” of pain) - raised $397.4 million gross ($363.9 million net) in its August IPO to fund a Phase 3 program and launch preparation for its lead pain pill, onzotrigine, plus two follow-on drugs (LTG-321 and LTG-418). Vertex’s Journavx, which is the only approved drug of its kind, sold $59.6 million in 2025 and $78.6 million in the first half of 2026 - costing $15.50 per pill relative to generic opioids that only co
Lp(a) Therapies in the Spotlight (opens the original)
Read excerpt
As a Fellow of the American Heart Association (FAHA) and human geneticist (PhD), I thought some folks might be interested in hearing me share my personal thoughts on Lp(a) in the wake of recent events. Specifically, here I’ll give four reasons I believe might shed additional light on why the trial failed in the spectacular way that it did, which I believe can be useful for making more informed decisions in trying to predict what may come next for the field or, alternatively, what probably won't
Nektar Therapeutics in the Spotlight (opens the original)
Read excerpt
By popular demand, we are releasing our models early to accommodate eager minds and loyal subscribers - apologies in advance for any typos/formatting issues.Boutique Biotech holds no position in . Not financial advice. Read more
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.